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Purpose: The relationship between antiCD20 therapy with rituximab and the lymphocytes 
phenotype in patients with rheumatoid arthritis was investigated, with an attempt to establish a 
relationship between commonly used clinical activity indices and variations in leukocyte count, 
in particular natural killer (NK) lymphocytes.
Methods: Patients with seropositive (cyclic citrullinated peptides and rheumatoid factor 
  positive) rheumatoid arthritis (according to the American College of Rheumatology 1987 criteria) 
refractory to conventional and antitumor necrosis factor-alpha agents who were subsequently 
treated with rituximab, a chimeric monoclonal antibody directed against CD20, were enrolled 
between January 2009 and September 2009. All subjects were treated with rituximab standard 
rheumatologic dose of 1.0 g on days 1 and 15 every 6 months for at least 2 years. A clinical 
evaluation was performed at baseline and subsequently every 3 months thereafter. At each 
assessment activated NK (CD56+/CD16+/CD54bright) cell count was collected and disease 
activity was assessed using Disease Activity Score in 28 Joints and the Simplified Disease 
Activity Index (SDAI).
Results: Thirty-four patients were enrolled (mean age ± standard deviation: 54.8 ± 12.8 years). 
Basal SDAI was 21.75 ± 5.4 and NK cell count mean value was 157.6 ± 90. After 24 months, 
SDAI was 14 ± 1.2 and NK cell count mean value was 301.7 ± 21 (P , 0.05). An inverted cor-
relation between SDAI and NK count was observed at 3 months (r = −0.36, P , 0.05), 6 months 
(r = −0.48, P , 0.45), 9 months (r = −0.47, P , 0.05), 12 months (r = −0.41, P , 0.01), 15 months 
(r = −0.58, P , 0.05), 18 months (r = −0.53, P , 0.05), 21 months (r = −0.68, P , 0.05), and 
24 months (r = −0.61, P , 0.05). A linear regression model between all variables collected and 
SDAI/Disease Activity Score in 28 Joints at 6 months and 12 months confirmed a significant 
relationship between SDAI/Disease Activity Score in 28 Joints and NK cell count.
Conclusion: The data confirm the clinical efficacy of rituximab and suggests the use of NK 
cells as a predictor of clinical response in patients with rheumatoid arthritis.
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Introduction
B cells have been implicated in the pathogenesis of rheumatoid arthritis (RA) since the 
discovery of circulating rheumatoid factor autoantibodies in RA patients. The success-
ful introduction of B cell-depleting monoclonal antibodies as a treatment for patients 
with refractory RA confirmed the important role of B cells in RA.1 Rituximab is a 
chimeric monoclonal antibody directed against the B cell-specific membrane protein 
CD20, which is used in the treatment of B cell malignancies and was approved for use 
in the treatment of patients with RA. The exact mechanism of influence in the immune 
responses in autoimmune disorders leading to clinical remission is not yet known. 
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B cell depletion and inhibition of antibody production are 
unlikely to explain all of its therapeutic effects.2–4 RA has a 
poorly understood pathogenesis, but the widely accepted view 
identifies rheumatoid factor as an epiphenomenon rather than 
an autoantibody directly implicated in disease. Furthermore, 
there is not a clear association between clinical improvement 
after rituximab therapy and B cell depletion, rheumatoid 
factor titer in RA, or lowering titers of anti-double-stranded 
DNA antibodies for lupus patients and, thus, research in 
rituximab therapy in autoimmune diseases includes seeking 
new biomarkers that may predict or measure therapeutic 
response.5,6
Natural killer (NK) cells are recognized by their cyto-
toxic and regulatory effects, implicated in prevention of 
  autoimmunity. For example, NK cell frequency in peripheral 
blood is lower in patients with lupus when compared to 
healthy subjects and decreased values of NK cell counts are 
associated with higher levels of anti-double-stranded DNA. 
T CD4+/CD25high cells are important natural modulators of 
self-antigen T cell-mediated responses. While such natural 
regulatory T cells are reduced in patients with systemic lupus 
erythematosus, inducible CD4+/interleukin 10+ regulatory T 
cell count increases in systemic lupus erythematosus patients 
probably as result of a compensatory mechanism.7–12 To date, 
the literature is lacking a clear, clinically useful, early predic-
tor of clinical response.13–17 In order to gain more insight into 
the clinical effects of B cell depletion in RA, the effects of 
antiCD20-mediated B cell depletion in the peripheral blood 
were investigated, with a focus on a possible relationship 
between NK activated cells (defined as CD56+/CD16+/
CD54 bright cells) and clinical response in terms of Disease 
Activity Score in 28 Joints (DAS28) and Simplified Disease 
Activity Index (SDAI).18
Methods
Patients and study design
All patients (enrolled between January 2009 and S  eptember 
2009) were diagnosed according to the 1987   American 
  College of Rheumatology (formerly, the American 
  Rheumatism Association) criteria for RA19 and were posi-
tive for both rheumatoid factor and anti-cyclic citrullinated 
peptides (CCP). All patients had RA refractory to standard 
antitumor necrosis factor drugs, and so were treated with 
rituximab every 6 months at standard rheumatologic dose of 
two 1000 mg intravenous infusions, separated by 2 weeks 
with 100 mg intravenous methylprednisolone or equiva-
lent before infusions, and accompanied by weekly 15 mg 
  subcutaneous methotrexate.
Disease activity
Disease activity was assessed using DAS28 and the compos-
ite index SDAI. SDAI is the numerical sum of five outcome 
parameters: tender and swollen joint counts (based on a 
28-joint assessment), patient and physician global assess-
ment of disease activity (visual analogue scale 0–100 mm), 
and level of C-reactive protein (normal ,1 mg/dL). The 
cut-off values for disease activity states are: remission #5, 
low disease activity #20, moderate disease activity #40, 
and high disease activity .40. Calculations of DAS28 were 
based on the following: number of swollen and tender joints 
(employing the 28-joint count), evaluator’s and/or patient’s 
global assessment of disease activity, C-reactive protein, or 
erythrocyte sedimentation rate. The following formula is the 
basis for the calculation:
DAS28 = (0.56 × TJC1/2) + (0.28 × SJC1/2)
+ (0.7 × ln[ESR]) + (0.014 × GH)
TJC and SJC represent tender and swollen joint count, 
respectively, ESR stands for erythrocyte sedimentation rate 
(mm/hour), and GH is patient’s general health, ie, assess-
ment of disease activity measured on a visual analog scale 
of 100 mm.
Flow cytometric analysis
Fresh blood was collected by venipuncture in ethylenedi-
aminetetraacetic acid-coated vials. Immunophenotyping 
was performed with the following monoclonal antibodies 
conjugated with fluorescein isothiocyanate, phycoerythrin, or 
phycoerythrin cyanine 5: CD54, CD16, CD56 (Immunotech, 
Marseille, France). The isotype-matched negative control 
used was mouse immunoglobulin G1 conjugated with fluo-
rescein isothiocyanate, phycoerythrin, or cyanine (MOPC-21) 
monoclonal antibodies (BD Pharmingen, Milan, Italy). Fluo-
rescence was measured using a FACScan™ flow cytometer 
(BD Biosciences, San Jose, CA). Briefly, 100 µL of blood 
was labeled with 10 µL monoclonal antibodies for 20 min-
utes in the dark. Red blood cells were removed by incubating 
the samples with lysing solution for 10 minutes in the dark. 
Tubes were centrifuged using a Hettich Zentrifugen EBA 21   
(Tuttlingen, Germany) for 5 minutes at 1200 rpm. Samples were 
treated further with washing solution and were centrifuged for 
5 minutes at 1200 rpm. Finally, cells were suspended in cell fixa-
tion solution and were ready for flow cytometry measurement. 
Lymphocytes were gated based on their forward and side-scatter 
characteristics. Information regarding the percentage of periph-
eral NK cells CD (CD56+/CD16+) expression was obtained. 
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As reported by Bowles et al,20 quantification of the number 
of NK cells with bright expression of CD54 is a reproducible 
marker for NK activation induced by monoclonal antibody-
coated tumor cells. The number of CD54bright NK cells was 
therefore evaluated as a measure of NK cell activation.
Statistical analysis
Pairwise comparisons were based on the Wilcoxon matched-
pairs signed-rank test. Correlation between variables was 
evaluated with Spearman’s rho.
All values of P , 0.05 were considered to indicate statis-
tical significance (two-tailed test). Linear regression models 
were estimated using all variables collected as covariates and 
SDAI and DAS28 as the dependent variable.
Results
Thirty-four patients were enrolled (mean age ± standard devia-
tion was 54.8 ± 12.8 years; 22 females, 12 males).   Disease dura-
tion at the first course of rituximab was 5.8 years. Rheumatoid 
factor mean values were 115 ± 25 at baseline, 53 ± 40 after 1 
year, and 47 ± 20 after 2 years (P , 0.05). CCP mean values 
were 86 ± 30 at baseline, 34 ± 25 after 1 year, and 39 ± 30 after 2 
years (P , 0.05). DAS28 was 5.25 ± 1.3 at baseline, 4.47 ± 0.7 
at 1 year, and 3.34 ± 1.1 after 2 years (P , 0.05). Basal SDAI 
was 31.75 ± 5.4 and NK cell count mean value was 157.6 ± 90. 
After 1 year SDAI was 18.3 ± 20.2 and NK cell count was 
221 ± 90 (P , 0.05). After 24 months SDAI was 14 ± 1.2 
and NK cell count was 301.7 ± 21 (P , 0.05). SDAI, DAS28, 
and NK cell count were assessed every 3 months. An inverse 
correlation between SDAI and NK cell count was observed at 
3 months (r = −0.36, P , 0.05), 6 months (r = −0.48, P , 0.05), 
9 months (r = −0.47, P , 0.05), 12 months (r = −0.41, 
P , 0.01), 15 months (r = −0.58, P , 0.05), 18 months 
(r = −0.53, P , 0.05), 21 months (r = −0.68, P , 0.05), and 
24 months (r = −0.61, P , 0.05) (Figures 1 and 2). Also, DAS28 
values were related to NK cell count at 3 months (r = −0.25, 
P , 0.05), 6 months (r = −0.38, P , 0.05), 9 months (r = −0.37, 
P , 0.05), 12 months (r = −0.51, P , 0.01), 15 months 
(r = −0.59, P , 0.05), 18 months (r = −0.57, P , 0.05), 
21 months (r = −0.61, P , 0.05), and 24 months (r = −0.58, 
P , 0.05). Subsequently, a linear regression least squares 
model backward method showed a significant correlation index 
between NK cell count modification at 3 months and SDAI/
DAS28 response at 6 months and 12 months (R2 = 0.73/0.71 
and 0.70/0.71, respectively; P , 0.05), independent from other 
variables collected (CCP, rheumatoid factor, C-reactive protein, 
and erythrocyte sedimentation rate values, age, and disease 
duration) (Figures 1 and 2).
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Figure 1 Relationship between Simplified Disease Activity Index values measured (Y axis) and predicted (X axis) at 6 months with a linear regression model based on natural 
killer cell count at 3 months.
Abbreviation: SDAI, Simplified Disease Activity Index. 
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Discussion
The role of B cells in immunopathogenesis of RA has not 
been fully characterized, but several possible mechanisms 
of action have been proposed: B cells may function as 
an antigen presenting cells with costimulatory signals 
required for T cell CD4 regulation, they may also secrete 
proinflammatory cytokines (eg, tumor necrosis factor, 
interleukin 6, and other chemokines), and may regulate 
immune response during RA contributing to inflammation 
and bone erosions.21,22 There is also recent evidence regard-
ing the involvement of NK cells in RA. NK cells originate 
from CD34+ hematopoietic progenitor cells and have been 
defined by flow cytometry as CD56+/CD16+ typical adult 
or mature cells, CD56+/CD16 immunoregulatory cells, 
and CD56−/CD16+ cytotoxic cells.23–25 NK cells have 
been detected in the synovium and elevated concentrations 
have been recorded in peripheral blood. NK cells may 
contribute to the pathogenesis of RA by perforin- or gran-
zyme-mediated cytotoxicity and cytokine production.26–30 
CD20-specific antibody rituximab has been proven to be a 
successful treatment for B cell malignancies and recently 
for RA. The binding of rituximab to CD20+ B cells results 
in B cell depletion through three mechanisms of action: 
antibody dependent complement mediated cytotoxicity, 
antibody-dependent cell-mediated cytotoxicity, and CD20+ 
B cell apoptosis. The depletion of peripheral B cells occurs 
immediately following the two infusions of rituximab, but 
different levels of clinical response have been achieved and 
therefore it is not possible to predict response on the basis 
of initial peripheral B cell depletion. NK cells appear to 
play a central role in mediating the effects of monoclonal 
antibody therapy including rituximab as effector cells 
of antibody-dependent cell-mediated cytotoxicity.20,31,32 
In a preliminary study in 2009, a probable reverse rela-
tionship between DAS28 response and NK cell count in 
patients treated with a single course of rituximab was 
suggested.33
In the present long-term study, the relationship between 
NK cell activation (defined as an upregulation of CD54) 
mediated by rituximab and clinical response in patients with 
active RA was evaluated. Also, the use of NK cell count was 
tested as a predictor of clinical response. The chief find-
ing was that the activation of NK cells 3 months after the 
first rituximab course was significantly related to clinical 
response at 6 months and 1 year, independent from other 
clinical variables such as C-reactive protein or CCP values, 
suggesting that NK activated cells can be used as an early 
predictor of clinical response.
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Figure 2 Relationship between Simplified Disease Activity Index values measured (Y axis) and predicted (X axis) at 12 months with a linear regression model based on 
natural killer cell count at 3 months.
Abbreviation: SDAI, Simplified Disease Activity Index. 
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